MRNA
Moderna, Inc. NASDAQ Listed Dec 7, 2018$48.54
Mkt Cap $19.3B
52w Low $22.28
70.5% of range
52w High $59.55
50d MA $51.60
200d MA $35.94
P/E (TTM)
-6.2x
EV/EBITDA
-4.2x
P/B
2.0x
Debt/Equity
0.2x
ROE
-32.6%
P/FCF
-5.6x
RSI (14)
—
ATR (14)
—
Beta
1.34
50d MA
$51.60
200d MA
$35.94
Avg Volume
8.1M
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
325 Binney Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | BMO | -3.02 | -3.40 | -12.6% | 45.94 | +1.5% | -1.2% | +3.0% | +1.7% | +6.2% | +5.7% | — |
| Feb 13, 2026 | BMO | -2.54 | -2.11 | +16.9% | 40.11 | +4.3% | +5.3% | +9.5% | +16.2% | +23.9% | +24.3% | — |
| Nov 6, 2025 | BMO | -1.87 | -0.51 | +72.7% | 23.56 | +7.1% | +3.3% | +4.2% | +5.1% | +12.1% | +13.4% | — |
| Aug 1, 2025 | BMO | -2.99 | -2.13 | +28.8% | 29.56 | -6.7% | -6.6% | -6.5% | -7.1% | -9.6% | -10.0% | — |
| May 1, 2025 | BMO | -2.92 | -2.52 | +13.7% | 28.54 | -3.0% | -5.3% | -3.3% | -2.5% | -14.4% | -15.7% | — |
| Feb 14, 2025 | BMO | -2.68 | -2.50 | +6.7% | 31.92 | -4.4% | +3.4% | +12.0% | +12.5% | +5.7% | +11.3% | — |
| Nov 7, 2024 | BMO | -1.91 | 0.03 | +101.6% | 51.81 | +9.2% | -3.0% | -9.6% | -17.5% | -16.1% | -18.7% | — |
| Aug 1, 2024 | BMO | -3.35 | -3.33 | +0.6% | 119.22 | -16.5% | -21.0% | -27.4% | -29.8% | -31.0% | -31.6% | — |
| May 2, 2024 | BMO | -3.56 | -3.07 | +13.8% | 111.46 | +3.1% | +12.7% | +12.1% | +9.6% | +8.6% | +9.4% | — |
| Feb 22, 2024 | BMO | -0.97 | 0.55 | +156.7% | 87.59 | +4.9% | +13.5% | +10.1% | +7.3% | +9.8% | +11.3% | — |
| Nov 2, 2023 | BMO | -2.01 | -1.39 | +30.8% | 76.20 | -15.6% | -6.5% | +1.7% | -5.4% | -3.3% | -6.4% | — |
| Aug 3, 2023 | BMO | -3.84 | -3.62 | +5.7% | 110.22 | -1.4% | -0.2% | -1.8% | -8.2% | -9.5% | -7.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $50.03 | $48.15 | -3.8% | -1.7% | -2.5% | +0.2% | +4.1% | +2.5% |
| Feb 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $49.87 | $48.70 | -2.3% | +0.8% | +1.3% | +3.0% | +3.7% | +7.4% |
| Feb 17 | Goldman Sachs | Maintains | Neutral → Neutral | — | $42.23 | $42.28 | +0.1% | +4.0% | +10.3% | +17.7% | +18.1% | +19.1% |
| Feb 17 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $42.23 | $42.28 | +0.1% | +4.0% | +10.3% | +17.7% | +18.1% | +19.1% |
| Feb 17 | Evercore ISI | Maintains | In Line → In Line | — | $42.23 | $42.28 | +0.1% | +4.0% | +10.3% | +17.7% | +18.1% | +19.1% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $29.63 | $29.46 | -0.6% | -0.6% | +1.0% | +0.9% | +3.0% | +4.5% |
| Nov 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $22.36 | $22.39 | +0.1% | +6.1% | +8.0% | +10.7% | +11.9% | +16.2% |
| Nov 21 | Leerink Partners | Maintains | Underperform → Underperform | — | $22.36 | $22.39 | +0.1% | +6.1% | +8.0% | +10.7% | +11.9% | +16.2% |
| Nov 21 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $22.36 | $22.39 | +0.1% | +6.1% | +8.0% | +10.7% | +11.9% | +16.2% |
| Nov 10 | BofA Securities | Maintains | Underperform → Underperform | — | $24.54 | $24.75 | +0.9% | +0.9% | +7.6% | +8.8% | +1.7% | +0.9% |
| Nov 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $24.33 | $23.87 | -1.9% | +0.9% | +1.8% | +8.5% | +9.8% | +2.6% |
| Oct 23 | Citigroup | Maintains | Neutral → Neutral | — | $26.85 | $25.82 | -3.8% | -2.2% | -0.4% | -0.7% | -5.6% | -8.0% |
| Oct 23 | UBS | Maintains | Buy → Buy | — | $26.85 | $25.82 | -3.8% | -2.2% | -0.4% | -0.7% | -5.6% | -8.0% |
| Oct 23 | JP Morgan | Maintains | Underweight → Underweight | — | $26.85 | $25.82 | -3.8% | -2.2% | -0.4% | -0.7% | -5.6% | -8.0% |
| Oct 20 | Needham | Maintains | Hold → Hold | — | $26.01 | $26.41 | +1.5% | +4.7% | +5.7% | +3.2% | +0.9% | +2.8% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $27.53 | $27.78 | +0.9% | -2.5% | -2.9% | -4.6% | +0.7% | -1.4% |
| Aug 22 | Leerink Partners | Maintains | Underperform → Underperform | — | $26.22 | $26.38 | +0.6% | +3.4% | -3.3% | -5.7% | -4.3% | -6.7% |
| Aug 4 | Barclays | Maintains | Equal Weight → Equal Weight | — | $27.61 | $28.02 | +1.5% | +0.1% | -0.5% | -3.3% | -3.6% | -5.4% |
| Jul 22 | BofA Securities | Maintains | Underperform → Underperform | — | $30.97 | $30.98 | +0.0% | +5.7% | +11.9% | +9.8% | +10.3% | +9.5% |
| May 22 | JP Morgan | Maintains | Underweight → Underweight | — | $25.80 | $25.50 | -1.2% | +3.6% | +1.8% | +3.7% | +1.0% | +4.4% |
| May 2 | UBS | Maintains | Buy → Buy | — | $27.03 | $27.74 | +2.6% | +2.1% | +3.0% | -9.6% | -11.0% | -9.8% |
| May 2 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $27.03 | $27.74 | +2.6% | +2.1% | +3.0% | -9.6% | -11.0% | -9.8% |
| May 2 | Evercore ISI | Maintains | In Line → In Line | — | $27.03 | $27.74 | +2.6% | +2.1% | +3.0% | -9.6% | -11.0% | -9.8% |
| May 2 | Barclays | Maintains | Equal Weight → Equal Weight | — | $27.03 | $27.74 | +2.6% | +2.1% | +3.0% | -9.6% | -11.0% | -9.8% |
| Apr 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $24.64 | $24.02 | -2.5% | +8.2% | -0.6% | +6.3% | +8.8% | +6.5% |
| Mar 21 | JP Morgan | Maintains | Underweight → Underweight | — | $32.45 | $32.05 | -1.2% | +0.6% | +5.3% | +4.3% | -3.0% | -1.0% |
| Feb 19 | UBS | Maintains | Buy → Buy | — | $35.75 | $35.11 | -1.8% | +0.4% | -5.7% | -0.6% | -5.2% | -6.9% |
| Feb 18 | Barclays | Downgrade | Overweight → Equal Weight | — | $32.99 | $33.05 | +0.2% | +8.4% | +8.8% | +2.2% | +7.7% | +2.8% |
| Feb 18 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $32.99 | $33.05 | +0.2% | +8.4% | +8.8% | +2.2% | +7.7% | +2.8% |
| Feb 11 | BofA Securities | Maintains | Underperform → Underperform | — | $31.87 | $31.52 | -1.1% | -2.9% | -4.2% | +0.2% | +3.5% | +12.2% |
| Jan 27 | Evercore ISI | Maintains | In Line → In Line | — | $41.41 | $40.87 | -1.3% | +0.6% | +8.5% | -1.7% | -0.9% | -4.8% |
| Jan 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $34.46 | $35.18 | +2.1% | +0.9% | -2.0% | -1.2% | +4.1% | +11.7% |
| Jan 8 | UBS | Maintains | Buy → Buy | — | $47.53 | $47.60 | +0.1% | -9.2% | -11.1% | -26.0% | -27.5% | -26.8% |
| Dec 18 | Argus | Downgrade | Buy → Hold | — | $40.76 | $40.05 | -1.7% | -5.9% | -2.9% | -3.4% | -2.9% | -1.2% |
| Nov 26 | JP Morgan | Maintains | Underweight → Underweight | — | $43.66 | $43.13 | -1.2% | -3.7% | -0.6% | -1.4% | +1.4% | -2.5% |
| Nov 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.85 | $38.31 | +4.0% | +7.2% | +1.2% | +0.2% | +3.8% | +11.6% |
| Nov 18 | HSBC | Upgrade | Hold → Buy | — | $36.85 | $38.31 | +4.0% | +7.2% | +1.2% | +0.2% | +3.8% | +11.6% |
| Nov 8 | Barclays | Maintains | Overweight → Overweight | — | $50.28 | $50.42 | +0.3% | -6.9% | -15.0% | -13.5% | -16.2% | -20.9% |
| Nov 4 | JP Morgan | Maintains | Underweight → Underweight | — | $54.63 | $54.60 | -0.1% | -2.0% | -2.5% | -5.2% | -8.0% | -14.3% |
| Oct 24 | UBS | Maintains | Buy → Buy | — | $53.39 | $53.39 | +0.0% | -1.1% | -0.6% | +2.6% | +3.4% | +2.5% |
| Aug 15 | JP Morgan | Maintains | Neutral → Neutral | — | $82.25 | $83.65 | +1.7% | +5.3% | +5.6% | +9.4% | +5.7% | +5.3% |
| Aug 6 | Deutsche Bank | Upgrade | Sell → Hold | — | $83.75 | $84.92 | +1.4% | -1.7% | -2.6% | +0.7% | +1.4% | -2.9% |
| Aug 5 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $86.58 | $80.37 | -7.2% | -3.3% | -4.9% | -5.8% | -2.6% | -1.9% |
| Aug 2 | Barclays | Maintains | Overweight → Overweight | — | $94.17 | $91.17 | -3.2% | -8.1% | -11.1% | -12.6% | -13.4% | -10.5% |
| Aug 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $94.17 | $91.17 | -3.2% | -8.1% | -11.1% | -12.6% | -13.4% | -10.5% |
| Aug 2 | Goldman Sachs | Maintains | Buy → Buy | — | $94.17 | $91.17 | -3.2% | -8.1% | -11.1% | -12.6% | -13.4% | -10.5% |
| Aug 2 | RBC Capital | Maintains | Outperform → Outperform | — | $94.17 | $91.17 | -3.2% | -8.1% | -11.1% | -12.6% | -13.4% | -10.5% |
| Jun 27 | Evercore ISI | Maintains | In Line → In Line | — | $122.45 | $121.90 | -0.4% | -1.0% | -3.0% | -5.3% | -4.4% | -5.3% |
| Jun 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $122.45 | $121.90 | -0.4% | -1.0% | -3.0% | -5.3% | -4.4% | -5.3% |
| Jun 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $148.39 | $150.00 | +1.1% | -0.5% | -2.1% | -5.6% | -7.1% | -10.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Hussain AbbasDir | — | Sell | 5,682 | $46.63 | $265K | 12,066 | -1.25% | — |
8-K · 1.01
!! High
Moderna, Inc. -- 8-K 1.01: Material Agreement
Moderna settled patent litigation with Arbutus Biopharma and Genevant Sciences, resolving all pending infringement disputes in U.S. courts effective March 3, 2026.
Mar 5
8-K
Moderna, Inc. -- 8-K Filing
Moderna reported $1.9 billion in 2024 revenue with a $2.8 billion net loss, while its U.S. influenza vaccine faced FDA rejection despite regulatory acceptance elsewhere, creating near-term headwinds.
Feb 13
8-K · 8.01
!! High
Moderna, Inc. -- 8-K 8.01: Material Event / Announcement
Moderna's investigational influenza vaccine mRNA-1010 received a Refusal-to-File letter from the FDA, halting regulatory review and delaying potential commercialization of this candidate program.
Feb 11
Data updated apr 26, 2026 1:16pm
· Source: massive.com